CATEGORIES

Don't Let Grandpa Get a New Girlfriend (Or Two)

And other lessons of paramount importance we can learn from the battle over Sumner Redstone’s media empire.

How to Have A Better Midlife Crisis

Millennials are trying to do their 40s differently than prior generations. They don’t really have a choice

THE BILLIONAIRE BOMB SCARE

When explosives were found outside Mukesh Ambani's home in Mumbai, the cops blamed terrorists. The truth-and the rot it exposed-was far more alarming

The Cold War at BEN&JERRY'S

The activist ice cream brand decided to pull out of Israel's occupied territories, setting off a legal battle with its owner, Unilever. What happens when a company Sues itself?

Fear Made John McAfee Rich. IT ALSO RUINED HIM

The cybersecurity pioneer’s long, strange saga started in Silicon Valley and ended in a Spanish prison By

WHAT GLAXO KNEW ABOUT ZANTAC

THE WORLD’S BESTSELLING HEARTBURN MEDICATION DIDN’T JUST CONTAIN A PROBABLE CARCINOGEN—IT CREATED IT. COURT DOCUMENTS SHOW THE DRUG’S MAKER DOWNPLAYED CRUCIAL INFORMATION FOR 40 YEARS

Chile's Green Hydrogen Ambitions

The country has the potential to be one of the lowest-cost producers of low-carbon fuels

The Perils of Survey Fatigue

Declining response rates threaten the quality of US economic statistics

Crypto Is on Thin Ice With Regulators

After the FTX scandal, digital-asset platforms face tough questions and wary banks

Green's Gray Areas

Al Gore wants to show that sustainability is profitable, but his firm’s results are complicated

Welcome Back, Low-Spending Tourists

Chinese budget tour groups were unpopular before Covid. Now nations covet their cash

A New Arms Race

As the war drags on, both Russia and Ukraine are using more shells than they can buy or produce

When No One Wins

A year into Putin’s war, the economic toll on Ukraine is obvious. But Russia is equally at risk

A Rolling Recession Is the Best Kind

A series of sectoral downturns may help subdue inflation without significant job losses

A Bet on High-End Bikes in Portugal

Frame maker Carbon Team says speedy delivery times give it an edge over Asian rivals

Call Me by My New Name

To come up with a winning moniker for your company, follow trends and consult a chatbot

A Billionaire's Tough Strategy Goes Awry

Jorge Paulo Lemann set stiff cost-cutting goals. Did Americanas brass go too far to meet them?

Financial Bubbles Are Hard to Pop

Despite appearing unsustainable, financial bubbles can last a surprisingly long time. Consider three: Japanese government bonds, the US stock market, and Chinese real estate.

Cracking the Case

A leather briefcase can last for decades. So you’d better choose the right one

Punch Shot

With Full Swing, Netflix tries to tease drama out of the most staid of sports: Golf.

GO HERE NOW - Amsterdam's New Era

A more cautious attitude toward tourism meets a progressive rethink of the canal city’s complex past

Girl With a Pearl Earring, one of 28 Vermeers on view at Amsterdam's Rijksmuseum - Her, Again?

An unprecedented Vermeer exhibition is the latest “once-in-a-lifetime” retrospective of one of the most famous artists of the Western canon. Here’s why these shows keep coming

SHELL GOES SUSTAINABLE-ISH

The oil giant is investing billions of dollars in renewables and other low-carbon energy solutions —and making record profits selling fossil fuels

CALL ME MAYBE?

When Zoom fatigue sets in, it's probably time to pick up the good ol’ telephone for a one-to-one Chat

THE TECH RESISTANCE MAKING OFFICE LIKE HELL

Advice on how to tackle ineptitude or strategic incompetence in the workplace

Britain to the Barricades

Strikes are paralyzing an economy that was already tottering

The Little Shop That Shook India

Nate Anderson’s Hindenburg Research makes money by making companies miserable

Dark Skies for The Cloud

There are signs of strain for a business that Big Tech has seen as its next big profit center

Selling Influence

Startup LTK helps creators find sponsorships and set up e-commerce operations

This Peanut Allergy Pill Is A Tough Nut to Crack

Nestlé spent $2.6 billion on Palforzia, but sales of the drug have been a disappointment, and the investment may be written down